This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.

开始日期2024-10-14

申办/合作机构

Liverpool School of Tropical Medicine

NCT06516042 / Recruiting临床3期IIT

Effectiveness, Feasibility, and Acceptability of Targeted Antimalarial Interventions for Seasonal Migrant Populations in Metema District, Amhara Region, Ethiopia

The purpose of the study is to assess the effectiveness, feasibility, and acceptability of targeted drug administration for seasonal migrant populations in Metema District, Amhara Region, Ethiopia

开始日期2024-08-21

申办/合作机构

Program for Appropriate Technology in Health

NCT06347471 / Recruiting临床4期IIT

The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy: a Longitudinal Study

A prospective study will be carried out in an area where parasites with reduced sensitivity to malaria drugs (artemisinins) have recently emerged. The study will recruit participants from patients who attend the clinic with uncomplicated malaria and are treated with conventional artemisinin-combination therapies (ACT) as part of standard clinical care. From this population, we will select P. falciparum gametocyte carriers.
Before, during and after ACT treatment, the transmission potential of artemisinin resistant and wild type infections will be assessed by microscopy, molecular methods, parasite culture and mosquito feeding assays. Parasite clearance will be determined in the first days (d0-3) after treatment.
The study population will consist of passively recruited patients with uncomplicated P. falciparum malaria who are microscopy positive for gametocytes. Participants will be treated with conventional therapies for uncomplicated malaria without randomization: artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA-PPQ). All doses are supervised. Parasite clearance is assessed ex vivo by ring-stage survival assays and by daily slides during the first days of treatment.
Gametocyte carriage and gametocyte commitment/production will be determined for resistant and wild type infections before, during and after treatment. In addition, venous blood will be collected at three timepoints to assess transmission to mosquitoes before (d0), during (d2) and after treatment (d7). The total duration of participation will be 7 days, the primary endpoint will be the reduction in mosquito infection rates at d2 (artemether-lumefantrine) or d7 (dihydroartemisinin-piperaquine) compared to pre-treatment.

开始日期2024-05-28

申办/合作机构

London School of Hygiene & Tropical Medicine

[+1]

100 项与双氢青蒿素哌喹相关的临床结果

登录后查看更多信息

100 项与双氢青蒿素哌喹相关的转化医学

登录后查看更多信息

100 项与双氢青蒿素哌喹相关的专利（医药）

登录后查看更多信息

254

项与双氢青蒿素哌喹相关的文献（医药）

2024-11-01·EBioMedicine

Intermittent preventive treatment for malaria in pregnancy and infant growth: a mediation analysis of a randomised trial

Article

作者: Roh, Michelle E. ; Nguyen, Anna T ; Ratnasiri, Kalani ; Tong, Yanwei ; Hanif, Suhi ; Kakuru, Abel ; Dorsey, Grant ; Nguyen, Anna T. ; Benjamin-Chung, Jade ; Jagannathan, Prasanna ; Roh, Michelle E

BACKGROUND:

Intermittent preventive treatment for malaria in pregnancy (IPTp) can improve birth outcomes, but whether it confers benefits to postnatal growth is unclear. We investigated the effect of IPTp on infant growth in Uganda and its pathways of effects using causal mediation analyses.

METHODS:

We analysed data from 633 infants born to mothers enrolled in a randomised trial of monthly IPTp with dihydroartemisinin-piperaquine (DP) vs. sulfadoxine-pyrimethamine (SP) (NCT02793622). Weight and length were measured from 0 to 12 months of age. Using generalised linear models, we estimated effects of DP vs. SP on gravidity-stratified mean length-for-age (LAZ) and weight-for-length Z-scores (WLZ). We investigated mediation by placental malaria, gestational weight change, maternal anaemia, maternal inflammation-related proteins, preterm birth, birth length, and birth weight. Mediation models adjusted for infant sex, gravidity, gestational age at enrolment, maternal age, maternal parasitaemia at enrolment, education, and wealth.

FINDINGS:

SP increased mean LAZ by 0.18-0.28 Z from birth through age 4 months compared to DP, while DP increased mean WLZ by 0.11-0.28 Z from 2 to 8 months compared to SP among infants of multigravidae; at these ages, confidence intervals for mean differences excluded 0. We did not observe differences among primigravida. Mediators of SP included birth weight, birth length, maternal stem cell factor, and DNER. Mediators of DP included placental malaria and birth length, maternal IL-18, CDCP1, and CD6 at delivery.

INTERPRETATION:

In high malaria transmission settings, this exploratory study suggests different IPTp regimens may influence infant growth among multigravidae, potentially through distinct pathways, in the exclusive breastfeeding period, when few other interventions are available.

FUNDING:

Stanford Center for Innovation in Global Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bill & Melinda Gates Foundation.

2024-10-01·EClinicalMedicine

Comparing approaches for chemoprevention for school-based malaria control in Malawi: an open label, randomized, controlled clinical trial

Article

作者: Vokhiwa, Maclean ; Sixpence, Alick ; Pitchford, Nicola J ; Magder, Laurence S. ; Cohee, Lauren M. ; Laufer, Miriam K ; Seydel, Karl B ; Magder, Laurence S ; Seydel, Karl B. ; Kumalakwaanthu, Wangisani ; Cohee, Lauren M ; Pitchford, Nicola J. ; Mathanga, Don P. ; Mathanga, Don P ; Laufer, Miriam K.

Background:

School-age children in sub-Saharan Africa suffer an underappreciated burden of malaria which threatens their health and education. To address this problem, we compared the efficacy of two school-based chemoprevention approaches: giving all students intermittent preventive treatment (IPT) or screening and treating only students with detected infections (IST).

Methods:

In a three-arm, open-label, randomized, controlled trial (NCT05244954) in Malawi, 746 primary school students, aged 5-19 years, were individually randomized within each grade-level to IPT (n = 249), IST with a high-sensitivity rapid diagnostic test (hs-RDT, n = 248), or control (n = 249). At six-week intervals three times within the peak malaria transmission season (February-June 2022) treatment with dihydroartemisinin-piperaquine (DP) was administered to girls <10 years and all boys, and chloroquine to older girls. The primary outcome was Plasmodium falciparum (Pf) infection detected by PCR 6-8 weeks after the final intervention. Secondary outcomes included anaemia, clinical malaria, and scores on tests of attention, literacy, and math. Analysis was by modified intention-to-treat.

Findings:

Outcomes analyses included 727 (97%) participants. At the end of the study, prevalence of Pf infection was 17% (41/243) in the IPT arm, 24% (58/244) in the IST arm, and 53% (127/240) in the control arm. Compared to controls, IPT and IST reduced the odds of Pf infection (IPT adjusted odds ratio [aOR]: 0.18 (95% CI: 0.11, 0.27); p < 0.0001; IST aOR: 0.27 (95% CI: 0.18, 0.40); p < 0.0001). However, only participants receiving IPT had a lower incidence of clinical malaria (0.19 cases per person per six months (95% CI: 0.14, 0.27) vs 0.56 (95% CI: 0.46, 0.68); incidence rate ratio: 0.38 (95% CI: 0.26, 0.55); p < 0.0001)) and prevalence of anaemia (8% [20/243] vs 15% [36/240]; aOR: 0.49 (95% CI: 0.27, 0.91); p = 0.023) compared to controls. Literacy scores were higher in both intervention arms. No between group differences in tests of attention or math or number of serious adverse events were found.

Interpretation:

Results support implementation of IST with hs-RDTs or IPT for reduction in the prevalence of infection. Based on reductions in clinical malaria, IPT may provide additional benefits warranting further consideration by school-based malaria chemoprevention programs.

Funding:

Doris Duke Charitable Foundation Clinical Scientist Development Award 2021191, U.S. NIH K24AI114996 & K23AI135076.

2024-09-17·MALARIA JOURNAL

Brugada syndrome precipitated by uncomplicated malaria treated with dihydroartemisinin piperaquine: a case report.

Article

作者: Tandean, Pendrik ; Rahmani, Muhammad Zaki ; Amir, Muzakkir ; Mukhtar, Irmayanti

BACKGROUND:

Cardiovascular events following anti-malarial treatment are reported infrequently; only a few studies have reported adverse outcomes. This case presentation emphasizes cardiological assessment of Brugada syndrome, presenting as life-threatening arrhythmia during anti-malarial treatment. Without screening and untreated, this disease may lead to sudden cardiac death.

CASE PRESENTATION:

This is a case of 23-year-old male who initially presented with palpitations followed by syncope and shortness of breath with a history of malaria. He had switched treatment from quinine to dihydroartemisinin-piperaquine (DHP). Further investigations revealed the ST elevation electrocardiogram pattern typical of Brugada syndrome, confirmed with flecainide challenge test. Subsequently, anti-malarial treatment was stopped and an Implantable Cardioverter Defibrillator (ICD) was inserted.

CONCLUSIONS:

Another possible cause of arrhythmic events happened following anti-malarial consumption. This case highlights the possibility of proarrhytmogenic mechanism of malaria infection and anti-malarial drug resulting in typical manifestations of Brugada syndrome.

项与双氢青蒿素哌喹相关的新闻（医药）

2024-11-29

·CPHI制药在线

抗疟疾药物研发进展

关注并星标CPHI制药在线在全球健康的版图中，疟疾一直是一块难以攻克的“顽疾”。据世界卫生组织（WHO）统计，2021年全球约有2.47亿疟疾病例，61.9万人因此失去生命，其中95%的病例和96%的死亡发生在撒哈拉以南非洲地区。疟疾不仅严重威胁人类健康，还对经济发展造成巨大阻碍，每年导致该地区约120亿美元的经济损失。今天，就让我们深入了解疟疾的现状、抗疟药物的研发进展，以及未来面临的挑战与希望。 1、现有抗疟疗法及耐药困境（1）常用药物与疗法当前，治疗非重症恶性疟原虫疟疾，主要依靠以青蒿素为基础的联合疗法（ACTs）。其中，蒿甲醚 - 苯芴醇（artemether lumefantrine，AL）在非洲市场占据了75%的份额，青蒿琥酯 - 阿莫地喹（artesunate amodiaquine）则作为二线选择，拥有24%的市场占有率。这些药物在一定程度上有效控制了疟疾的发展，但它们也面临着日益严峻的耐药问题。除了ACTs，还有双氢青蒿素 - 哌喹（dihydroartemisinin piperaquine，DHA - PPQ）、阿托伐醌 - 氯胍（atovaquone proguanil，Malarone）等药物组合，但使用相对较少。对于重症疟疾，静脉注射青蒿琥酯（artesunate）是首选治疗方法，金鸡纳霜（quinine）也可作为替代选择。而针对间日疟原虫疟疾的根治，氯喹（Chloroquine）与伯氨喹（primaquine）或他非诺喹（tafenoquine）的联合使用是常见方案；孕期间歇性预防治疗则采用磺胺多辛 - 乙胺嘧啶（sulfadoxine-pyrimethamine，SP）；在非洲的季节性疟疾高发地区，对于6个月至5岁（部分国家至10岁）的儿童，每月使用SP和阿莫地喹进行季节性疟疾化学预防（SMC）（图1）。（2）药物耐药性问题疟原虫耐药问题由来已久，20世纪初有对奎宁耐药的报告，50年代起氯喹和SP耐药性在疟疾流行区扩散，致死亡人数上升。21世纪ACTs虽为一线疗法，但耐药问题仍存。东南亚大部分地区DHA - PPQ因耐药失效，非洲大陆AL虽仍有效，但卢旺达已现青蒿素部分耐药，乌干达恶性疟原虫临床分离株对咯萘啶（pyronaridine）和DHA敏感性降低，这些耐药现象严重威胁全球疟疾防控成效。图1.在疟原虫生命周期下的疟疾治疗来源：出自参考文献【1】 2、抗疟药物研发进展（1）传统与现代的研发策略在抗疟药物研发的漫长历程中，传统策略主要包括从天然产物中分离和修饰活性成分，以及筛选化合物库、设计已知靶点抑制剂等。然而，这种基于天然产物的研发方式面临着诸多挑战，如供应不稳定、成分多变、生物测定引导分馏后复杂混合物相关的实际挑战。此外，对现有天然产物进行改进以克服耐药性的难度较大，这使得研发人员不得不寻求新的方法。随着科学技术的发展，现代抗疟药物研发主要采用表型筛选和基于靶点和虚拟药效团的方法。表型筛选：通过对全细胞寄生虫培养进行大规模化学库筛选，可发现具有新颖作用模式的化合物，许多在研药物由此发现，但靶点未知会给后续优化带来困难。基于靶点和虚拟药效团方法：基于靶点的方法可开发新的生化测定，合理设计化合物，但可能成本高且存在耐药风险；虚拟筛选虽初期成本低，但需大量后续工作确认化合物与靶点的结合及对寄生虫的功能抑制，目前尚未产生具有强细胞活性的新化合物。（2）新靶点及治疗药物为了开发更有效的抗疟药物，科学家们已经发现了一些具有潜力的靶点，如细胞色素B（CytB）、二氢蝶酸合成酶（DHPS）、二氢叶酸还原酶 - 胸苷酸合成酶（DHFR - TS）和血红素等，这些都是已有的临床验证靶点（图2）。此外，还有一些较新的靶点，如ATP酶4（ATP4）、延伸因子2（eEF2）、脯氨酰tRNA合成酶（PRS）和磷脂酰肌醇4 - 激酶（PI4K）等。图2.具有临床验证的抗疟靶点来源：出自参考文献【1】在抗疟药物的研发进程中，众多药物处于不同的研究阶段（图3），给我们带来了新的希望。患者探索阶段： ZY - 19489是一种快速杀伤无性血液阶段寄生虫且耐药倾向低的化合物，在志愿者感染研究中，其安全性、药代动力学和抗疟活性表现优异，支持其进一步开发。 ferroquine是一种含二茂铁基环的4 - 氨基喹啉类药物，具有快速杀伤和长半衰期的特点，与ZY - 19489组合使用，有望实现儿童疟疾的单剂量治疗，为应对ACTs耐药性提供了潜在解决方案。 cabamiquine对寄生虫无性肝、血和性阶段均有活性，但其耐药性发展较快，因此与咯萘啶联用，以增强疗效并延缓耐药性的产生。 ganaplacide对无性肝、血和性阶段的恶性疟原虫均有强效作用，与优化配方的苯芴醇联用，在临床研究中取得了积极结果，有望成为自2000年以来首个非ACT治疗药物。 cipargamin可使寄生虫僵化并快速清除，对传播阻断也有效，但由于存在耐药风险，目前正在探索注射用新配方，以确保其长期有效性。临床I期阶段： atoguanil是阿托伐醌 - 氯胍的新配方，旨在提高药物的疗效和安全性。 MMV688533是通过基于同源性的筛选策略发现的TCP - 1候选药物，其作用机制虽尚未完全明确，但耐药风险低，在实验室条件下难以产生耐药性，目前正在进行临床I期研究。 INE963是诺华发现的快速杀伤化合物，对无性血液阶段寄生虫具有高效作用，且耐药倾向低，近期已进入临床I期试验，后续还将在治疗组合的II期试验中进行评估。临床前阶段：共有11种候选小分子和1种抗体正在深入研究。其中， MMV183是一种抑制AcAS的抗代谢物，具有显著的传播阻断和无性血液阶段活性； GSK701是酰基辅酶A合成酶ACS10和ACS11的新型抑制剂，具有TCP - 1活性特征； WM382和BRD5018分别是 plasmepsins IX和X以及FRS的抑制剂，具有多阶段活性，对寄生虫的多个生命周期阶段均有作用； SC83288是一种新型注射候选药物，用于治疗重症疟疾，但其作用机制尚不清楚； GSK484和IWY357是通过表型筛选发现的快速杀伤化合物，具有低耐药倾向，虽然其结构和作用机制尚未公布，但在抗疟药物研发中具有潜在价值； MMV371是阿托伐醌前药，ELQ - 331是ELQ - 300的口服前药，两者均通过抑制寄生虫CytB发挥作用； S011 - 1793是下一代4 - 氨基喹啉，能够克服氯喹和PPQ耐药性； MMV1793609是PfATP4抑制剂，具有低剂量高效的特点，是2022年发现的备选药物。图3.抗疟药物研发进展和研发管线来源：出自参考文献【1】 3、抗疟之路的未来挑战与展望疟疾防控工作面临着诸多复杂的挑战，疟原虫耐药机制研究复杂，实验室研究多基于单基因变化，但实际临床分离株往往涉及多个突变，且寄生虫遗传背景对耐药性产生的影响机制尚不明确，不同地区疟原虫的遗传差异也导致耐药性表现和传播方式各异。此外，药物递送与药代动力学也存在难题，例如长效注射剂面临疗效持续时间、体积和安全性等挑战，不同人群对药物代谢和反应的差异也增加了研发复杂性...... 尽管挑战重重，但过去15年在疟疾防控方面取得了一定成果，新靶点不断被发现，候选药物进入研发管线，新治疗方法如首个疟疾疫苗获批问世。这些成绩的取得离不开全球各方的紧密合作，未来仍需进一步加强合作，整合资源、加大研发投入、鼓励创新，通过共享数据、技术和经验来加速抗疟药物研发进程，实现疟疾的有效控制和消除。疟疾防控是全球性持久战，每一次突破都使我们向战胜疟疾的目标更近一步，我们应共同关注和支持抗疟工作，期待人类能早日摆脱疟疾威胁。参考文献 [1]Siqueira-Neto, Jair L et al. “Antimalarial drug discovery: progress and approaches.” Nature reviews. Drug discovery vol. 22,10 (2023): 807-826. doi:10.1038/s41573-023-00772-9 [2]Carter, Richard, and Kamini N Mendis. “Evolutionary and historical aspects of the burden of malaria.” Clinical microbiology reviews vol. 15,4 (2002): 564-94. doi:10.1128/CMR.15.4.564-594.2002 [3]Rasmussen, Charlotte et al. “Current and emerging strategies to combat antimalarial resistance.” Expert review of anti-infective therapy vol. 20,3 (2022): 353-372. doi:10.1080/14787210.2021.1962291 END 【智药研习社近期直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床研究孤儿药

2024-01-13

·Science Daily

African women living with HIV have an effective option to prevent malaria during pregnancy

In women living with HIV, preventive treatment with DHA-PPQ is a safe and effective strategy to prevent malaria during pregnancy, according to the final results of the MAMAH clinical trial. In women living with HIV, preventive treatment with DHA-PPQ is a safe and effective strategy to prevent malaria during pregnancy, according to the final results of MAMAH, a clinical trial funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) and coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation. The study, published in the Lancet Infectious Diseases, could help protect the health of the estimated one million pregnant women who suffer from a double infection with malaria and HIV every year. Pregnant women are particularly vulnerable to malaria infection. Hence the recommendation to offer preventive treatment (IPTp) based on sulphadoxine and pyrimethamine (SP) to pregnant women living in malaria-endemic areas. The problem is that these drugs are incompatible with co-trimoxazole (CTX), an antibiotic given to people with HIV to prevent bacterial infections. "This means that the population most vulnerable to malaria infection and its consequences, namely pregnant women living with HIV, are also the least protected," explains ISGlobal researcher Raquel González, technical coordinator of the MAMAH project, led by Clara Menéndez, director of ISGlobal's Maternal, Child and Reproductive Health Initiative. The aim of the project was to evaluate the safety and efficacy of two other drugs: dihydroartemisinin and piperaquine (DHA-PPQ) to prevent malaria during pregnancy in women living with HIV. The research team conducted the trial in Gabon and Mozambique with more than 600 pregnant women taking CTX in addition to antiretroviral treatment for HIV. One group of pregnant women received DHA-PPQ and the other group received a placebo. Lower risk of malaria infection and disease Although there was no significant difference in malaria infection at the time of delivery, women in the DHA-PPQ group had a significantly lower risk of developing clinical malaria throughout pregnancy (almost eight times lower than the placebo group) and also a lower risk (almost half) of becoming infected. DHA-PPQ was effective in women taking different antiretroviral treatments. No serious side effects were observed, and DHA-PPQ had no effect on mother-to-child transmission of HIV. "We show that preventive treatment with DHA-PPQ is effective even in low malaria transmission settings," says Gonzalez. "Adding this strategy to malaria control tools could significantly improve the health of thousands of mothers and their babies, especially in sub-Saharan Africa, a region where an estimated one million women living with HIV are infected with malaria during pregnancy every year," she adds. "We congratulate the MAMAH team on these important results in the field of malaria research, and, in particular, in providing better health to pregnant women living with HIV in malaria-endemic areas," says Montserrat Blázquez-Domingo, EDCTP Senior Project Officer. "This study underlines the value of collaborative research that EDCTP supports and our focus on priority infectious disease affecting sub-Saharan Africa in populations often excluded from clinical trials -- such as pregnant women." The MAMAH study is part of the EDCTP2 Programme supported by the European Union (grant number RIA2016MC-1613-MAMAH).

临床结果临床研究

2021-09-23

·E药经理人

【闪耀西普】昆药总裁钟祥刚：传承精华、守正创新，赋予传统中医药新的生命力

2021西普会 | 中国健康产业资本峰会变革与机遇相伴，行业格局重塑之中，中医药企业该如何获得竞争优势、最大限度分享行业红利？9月23日，西普会中国健康产业资本峰会上，昆药集团总裁钟祥刚先生就医药新政下品牌中药的发展机遇与战略选择进行了主题演讲。他认为，面对消费提质扩容和中医药国际化的内外双循环机遇，中医药振兴发展正进入一个高光时刻，而创新将是发展的主旋律。因此，站在“传统中医药”这位巨人肩膀上的创新发展，既是中药企业应对行业深度变革的战略选择，也是突破企业所面临的发展瓶颈的必由之路。文明瑰宝，创新步履不停相信中医药的发展是中华民族的文化自信。中医药学包含着中华民族几千年的健康养生理念及其实践经验，是中华文明的一个瑰宝，凝聚着中国人民和中华民族的博大智慧，其在疾病预防、治疗、康复等方面的独特优势受到许多国家民众的认可。传承精华、守正创新，作为国内天然植物药领先企业，昆药集团已经在中医药发展的道路上走过了七十年。作为全球第一家青蒿素生产企业以及三七制剂国家标准的制定者，昆药集团持续推动青蒿在其他疾病治疗领域的创新研发与探索，带动三七等植物药优势产业的可持续、高质量发展。钟祥刚表示，昆药集团的创新转型，是基于其在植物药和精品国药领域的深耕细作和谋篇布局，结合研发与技术创新，在产品功效及新的疾病治疗领域不断实现创新突破，赋予传统中医药新的生命力。战略选择，聚焦优势领域医疗意识的增强与消费水平的提升，将共同推动国内医药市场尤其是健康消费市场的快速增长。对于昆药集团来说，如何把握新经济下消费升级新趋势，从慢病、养生、大健康、医美、治未病等全方位出发，搭建成熟的生态网络决定了其是否能在竞争激烈的医药健康赛道上占据一席之地。钟祥刚表示，在新的历史交汇点，昆药已明确战略目标、路径和竞争力。为确保“中国品牌中药企业TOP10”的战略目标早日实现，昆药坚持“一面红旗”不动摇，即研发创新，聚焦心脑血管、骨科、肾科、风湿免疫等治疗领域；紧握植物药和精品国药“两把尖刀”，打造三七创新科技领导者品牌，传承国药精髓。同时，突出差异化领域研发能力，聚焦细分产品领域，强化本土化商业能力。战略导向下，昆药集团以“昆药血塞通”和“昆中药1381”两大品牌口服产品作为突破口，打造黄金单品，带动产品集群实现快速增长。从数据来看，昆药集团“黄金单品”昆药血塞通软胶囊、参苓健脾胃颗粒、舒肝颗粒等，均实现放量增长，潜力产品持续涌现，昆药血塞通片、灯银脑通胶囊、香砂平胃颗粒、草乌甲素软胶囊等成为口服产品阵营中的新生力军，产品纵深及梯度布局轮廓清晰，整体收入结构更趋均衡。未来可期，打造第二增长曲线稳健的财务结构，持续的盈利增长以及稳定的现金分红是企业长期回报的重要保障。昆药集团一方面坚持以品牌力、产品力、渠道力和创新力持续巩固和构建细分赛道的护城河和竞争壁垒，通过自主研发、外部合作、投资并购多渠道开拓创新研发路径，搭建四大BD团队，构建产品管线；一方面依托在植物药领域的研发底蕴及技术优势，在高景气赛道进行产品和产业布局，实现三七、青蒿在医美大健康新赛道产业链价值最大化，以此推动企业不断实现迭代升级和自我超越，打造企业第二增长曲线。不仅如此，昆药集团与盖茨基金会合作，正在积极推动青蒿素主打产品“科泰复”的PQ认证；与中国中医科学院（屠呦呦团队）合作的、适用于治疗红斑狼疮的项目已进入II 期临床试验。同时，全球各国正积极探索青蒿素衍生物新的治疗领域。青蒿素未来可期，或将带来更多意外惊喜。的治疗领域不仅如此，昆药集团与盖茨基金会合作，正在积极推动青蒿素主打产品“科泰复”的PQ认证；与中国中医科学院（屠呦呦团队）合作的、适用于治疗红斑狼疮的项目已进入II 期临床试验。同时，全球各国正积极探索青蒿素衍生物新的治疗领域。青蒿素未来可期，或将带来更多意外惊喜。钟祥刚表示，现在的昆药集团拥有超过40个自主研发药物、超过140个精品国药、超过200人的研发精英团队以及超过2000人的销售精英团队，构建了公司扎实稳健的发展基石。在承前启后的历史节点，昆药集团将紧紧把握“健康中国”建设及新经济下消费升级的契机，从“药品供应商”向“健康服务（管理）专家”转型，厚积薄发全面发力医药大健康产业布局，持续以优质的产品和服务满足消费者的需求，不断创造价值，持续让股东分享企业成长红利。

100 项与双氢青蒿素哌喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	双氢青蒿素哌喹	P01BF05	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶性疟	中国	贝克诺顿（浙江）制药有限公司	2004-12-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间日疟原虫感染	临床3期	巴西	-	2018-07-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Lancet Glob Health	N/A	妊娠期感染性疾病	-	IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention	衊壓範繭膚積鹹餘積簾(鏇簾憲鹹壓艱鹹餘廠製) = 夢鹹壓願繭獵繭鏇鹽鏇醖廠鏇鹽淵窪獵蓋齋構 (範衊鹽憲鑰鹹憲簾積範 ) 更多	-	2024-10-01
				IPTp with dihydroartemisinin-piperaquine only	衊壓範繭膚積鹹餘積簾(鏇簾憲鹹壓艱鹹餘廠製) = 簾築鹹夢齋獵願範餘獵醖廠鏇鹽淵窪獵蓋齋構 (範衊鹽憲鑰鹹憲簾積範 ) 更多
NCT05160363 (CTgov)	临床1期	-	37	Piperaquine tetraphosphate+Pyronaridine Tetraphosphate (PYR and PQP Combination)	觸膚繭襯顧鏇衊構觸襯(鹽鏇選艱網窪選鏇願網) = 壓鏇遞衊觸醖鹹鑰淵壓蓋網襯構餘顧鹽觸鬱簾 (鏇蓋膚餘獵鬱糧襯鹹願, 鏇壓繭願獵鹹選廠廠築 ~ 構壓構醖窪艱構簾壓艱) 更多	-	2024-05-10
				Placebo+Pyronaridine Tetraphosphate (PYR and Placebo Combination)	觸膚繭襯顧鏇衊構觸襯(鹽鏇選艱網窪選鏇願網) = 簾顧夢顧範夢衊鬱積顧蓋網襯構餘顧鹽觸鬱簾 (鏇蓋膚餘獵鬱糧襯鹹願, 夢餘顧獵範壓願鑰鬱鬱 ~ 襯醖遞餘鹽觸廠壓願壓) 更多
NCT03178643 (EPiTOMISE, CTgov)	临床4期	恶性疟 \| 镰状细胞血症	246	Proguanil Oral Tablet (Proguanil Oral Tablet)	顧鬱觸齋築廠醖鹽窪鏇(繭壓蓋糧鬱顧鑰鹹觸鹹) = 繭網遞簾衊襯範衊蓋齋淵壓餘鹽艱範夢簾願鹽 (選積淵醖獵醖觸選簾衊, 鑰壓鹹夢艱衊糧鑰膚餘 ~ 夢衊艱憲衊觸觸夢鏇製) 更多	-	2024-03-27
				Sulfadoxine/pyrimethamine+Amodiaquin (Sulfadoxine/Pyrimethanine-Amodiaquine)	顧鬱觸齋築廠醖鹽窪鏇(繭壓蓋糧鬱顧鑰鹹觸鹹) = 醖繭選鑰淵顧夢餘積鹽淵壓餘鹽艱範夢簾願鹽 (選積淵醖獵醖觸選簾衊, 積窪顧簾膚夢遞壓膚構 ~ 憲壓構遞醖鬱選餘製膚) 更多
NCT00852371 (CTgov)	临床3期	疟疾	780	Dihydroartemisinin-Piperaquine (Dihydroartemisinin-piperaquine)	齋網簾醖鑰蓋襯網構淵(簾選餘積憲繭獵衊鹹衊) = 鏇築壓選醖觸顧顧鑰鑰壓簾糧醖鏇顧網構齋艱 (艱窪膚鑰製蓋膚範糧衊, 淵願鹹築鬱淵網顧選窪 ~ 廠獵獵蓋觸網獵艱獵夢) 更多	-	2024-03-21
				sulfadoxine-pyrimethamine+amodiaquine (Combination of Amodiaquine +Sulfadoxine-pyrimethamine)	齋網簾醖鑰蓋襯網構淵(簾選餘積憲繭獵衊鹹衊) = 願餘夢衊積鏇餘獵淵網壓簾糧醖鏇顧網構齋艱 (艱窪膚鑰製蓋膚範糧衊, 顧齋築遞壓窪淵繭襯襯 ~ 鏇壓蓋繭醖鑰築淵範簾) 更多
NCT04158713 (Pubmed \| Lancet) 人工标引	临床3期	疟疾 HIV	895	Co-trimoxazole p dihydroartemisinin-piperaquineine	醖鹹遞憲憲齋獵醖鹽壓(齋艱齋憲夢壓獵積淵遞) = 選醖獵鏇糧夢鏇衊壓膚獵壓製齋鬱築醖鏇願餘 (製鏇顧憲願獵獵餘膚網 ) 更多	积极	2024-01-01
				Co-trimoxazole plus placebo	醖鹹遞憲憲齋獵醖鹽壓(齋艱齋憲夢壓獵積淵遞) = 鹽鬱顧鏇鏇網選糧鏇夢獵壓製齋鬱築醖鏇願餘 (製鏇顧憲願獵獵餘膚網 ) 更多
NCT03178643 \| PACTR201707002371165 (Pubmed \| PLoS Med)	临床4期	镰状细胞血症	246	Proguanil	壓鏇簾艱範範襯鑰願簾(蓋範繭憲積簾膚鬱艱選) = Serious adverse events were common and distributed between groups, although compared to daily Proguanil (n = 2), more children died receiving monthly SP-AQ (n = 7; hazard ratio [HR] 5.44; 95% CI: 0.92 to 32.11; p = 0.064) but not DP (n = 1; HR 0.61; 95% CI 0.04 to 9.22; p = 0.89), although differences did not reach statistical significance for either SP-AQ or DP 憲簾鏇繭襯壓簾製淵鹹 (鑰觸糧簾蓋積願壓膚鬱 )	不佳	2022-10-10
NCT02793622 (Pubmed \| Clin Infect Dis)	临床3期	-	782	Dihydroartemisinin-piperaquine (DHA-PQ)	齋醖餘艱鬱積艱繭糧糧(選醖觸繭獵襯鹽願襯憲) = Nine women given DHA-PQ had grade 3-4 cardiac adverse events 衊艱齋鏇鑰蓋餘襯醖製 (膚鏇衊窪網窪憲鑰築鏇 )	-	2021-12-02
NCT02163447 (Pubmed \| Nat Commun)	临床3期	疟疾	300	DP every 4 weeks	鹹衊憲廠壓鬱範襯鹹觸(遞製鑰糧襯廠膚膚鏇憲) = 獵壓憲艱糧觸膚窪繭願鑰膚蓋顧觸簾鏇觸範艱 (積夢顧製餘願積繭繭繭 ) 更多	-	2021-11-18
NCT01054248 (Pubmed \| BMC Med)	临床3期	妊娠期感染性疾病	511	Dihydroartemisinin-piperaquine (DP)	壓製蓋膚憲選製醖願餘(壓鹹積鹹窪鏇鏇餘齋範) = 獵構構襯獵築廠衊網廠鏇網衊襯鏇齋鏇淵簾顧 (網鏇廠網淵鑰糧顧築醖, 81.6 ~ 97.9) 更多	-	2021-06-10
				Artesunate-mefloquine (ASMQ)	壓製蓋膚憲選製醖願餘(壓鹹積鹹窪鏇鏇餘齋範) = 餘憲鹽廠醖構醖齋蓋鏇鏇網衊襯鏇齋鏇淵簾顧 (網鏇廠網淵鑰糧顧築醖, 66.1 ~ 88.1)
NCT02315690 (Pubmed \| BMJ Glob Health)	临床3期	疟疾	4,000	Reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine	選糧窪膚壓鑰餘糧願鏇(築齋糧醖鬱衊鹽憲範製) = 蓋衊夢壓膚憲襯鏇糧獵顧築選築築膚製夢膚選 (蓋蓋夢遞衊選製選遞衊, 1.00 ~ 1.67)	-	2021-06-01
				Reactive case detection (RACD) involving RDTs and artemether-lumefantrine	選糧窪膚壓鑰餘糧願鏇(築齋糧醖鬱衊鹽憲範製) = 廠構網範膚蓋觸簾醖鬱顧築選築築膚製夢膚選 (蓋蓋夢遞衊選製選遞衊, 0.71 ~ 1.34)